The Kobe University Human Intestinal Microbiota Model for gut intervention studies
- PMID: 33718974
 - DOI: 10.1007/s00253-021-11217-x
 
The Kobe University Human Intestinal Microbiota Model for gut intervention studies
Abstract
The human gut harbors a complex microbial community that performs a range of metabolic, physiological, and immunological functions. The host and its inhabiting microorganisms are often referred to as a "superorganism." Dysbiosis of gut microflora has been associated with the pathogenesis of intestinal disorders including inflammatory bowel disease, colorectal cancer, and extra-intestinal disorders such as cardiovascular disease. Therefore, gut microbiome interventions are important for the prevention and treatment of diseases. However, ethical, economic, scientific, and time constraints limit the outcome of human intervention or animal studies targeting gut microbiota. We recently developed an in vitro batch fermentation model (the Kobe University Human Intestinal Microbiota Model, KUHIMM) that is capable of hosting a majority of gut microbial species in humans and also detects the metabolites produced by microorganisms in real time. In this mini review, we elucidated the characteristics of the KUHIMM and its applicability in analyzing the effect of diet, drugs, probiotics, and prebiotics on intestinal bacteria. In addition, we introduce as examples its application to disease models, such as ulcerative colitis, in which intestinal bacteria are intricately involved in the process of pathogenesis. We also discuss the potential of the KUHIMM in precision medicine. KEY POINTS: • In vitro gut fermentation model to simulate human colonic microbiota • Screening of potential prebiotics and probiotic candidates in healthy model • Construction of disease models of ulcerative colitis and coronary artery disease.
Keywords: Coronary artery disease; Gut; In vitro model; Microbiota; Ulcerative colitis.
References
- 
    
- Aguirre M, Eck A, Koenen ME, Savelkoul PHM, Budding AE, Venema K (2016) Diet drives quick change in the metabolic activity and composition of human gut microbiota in a validated in vitro gut model. Res Microbiol 167:114–125. https://doi.org/10.1016/j.resmic.2015.09.006 - DOI - PubMed
 
 - 
    
- Bambery B, Selgelid M, Weijer C, Savulescu J, Pollard AJ (2016) Ethical criteria for human challenge studies in infectious diseases. Public Health Ethics 9:92–103. https://doi.org/10.1093/phe/phv026 - DOI - PubMed
 
 - 
    
- Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ (2015) Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 26:26191. https://doi.org/10.3402/mehd.v26.26191 - DOI - PubMed
 
 - 
    
- Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C, Rosewarne CP, Bickley C, Peters C, Schoeman MN, Conlon MA, Roberts-Thomson IC, Andrews JM (2019) Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321:156–164. https://doi.org/10.1001/jama.2018.20046 - DOI - PubMed - PMC
 
 - 
    
- Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28:1221–1227. https://doi.org/10.1136/gut.28.10.1221 - DOI - PubMed - PMC
 
 
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
